Payen 2001 Behavioral Pain Scale from three caller-assigned 1-4 items (facial_expression, upper_limbs, ventilator_compliance) using that paper's Table 1 descriptors. magent sums only (range 3-12) and does not observe the patient. No later pain-present cutoffs. Not a pain diagnosis or analgesic order. Not CPOT (CPOT items are 0-2).

AMT-4 (Swain 1997): four caller-assigned flags for age, date of birth, place, and year. Each correct item scores 1; max 4. Impaired cognition is indicated when the score is less than 4 (0–3 impaired; 4 not impaired). Flags only; magent does not interview the patient or collect a date of birth, age, place name, or year. Not a dementia diagnosis and not a medical device. Not Hodkinson 1972 AMT-10.

Solal-Céligny 2004 FLIPI: age >60, Ann Arbor III–IV, hemoglobin <120 g/L, nodal areas >4, LDH above ULN; 1 point each, max 5. Low 0–1, intermediate 2, high ≥3. Deterministic published score with citation; not a follicular-lymphoma diagnosis or treatment choice; FLIPI 2004 not FLIPI-2. magent does not stage lymphoma, assay hemoglobin, count nodal sites, or measure LDH.

Soumerai 2019 BALL score for relapsed or refractory CLL. Four caller-assigned 1-point flags (max 4): beta-2-microglobulin at the paper's published cutoff (>=5 mg/dL), LDH > laboratory ULN, anemia (Hb <110 g/L women or <120 g/L men), and time from initiation of last therapy <24 months. Risk low 0-1, intermediate 2-3, high 4. magent does not assay labs or convert B2M mg/L vs mg/dL. Not a treatment recommendation.

Absolute lymphocyte count from WBC and lymphocyte percent (Shapiro 1998). ALC < 1000 cells/mm3 predicts CD4 < 200; ALC >= 2000 predicts CD4 >= 200. Deterministic published arithmetic with citation. Not a CD4 measurement or HIV diagnosis. magent does not measure the CBC.

Sorror 2005 HCT-specific comorbidity index. Seventeen caller-assigned comorbidities with published weights 1, 2, or 3 (max 26). Pulmonary moderate vs severe and hepatic mild vs moderate/severe are mutually exclusive. Risk groups: 0 low, 1–2 intermediate, ≥3 high. Caller supplies the published category; magent does not interpret PFTs or echo and does not list for transplant. Not Charlson. Not a diagnosis. Not a medical device.

Mentzer index as MCV in fL divided by RBC count in millions per µL (Mentzer 1973 Lancet letter). Quotient <13 favors β-thalassaemia trait; >13 favors iron deficiency; 13 is indeterminate. Deterministic published arithmetic with citation. Not a diagnosis of thalassemia or iron deficiency; magent does not apply later cutoffs that are not in that letter.

CLL-IPI 2016 for chronic lymphocytic leukaemia: TP53 abnormality (del(17p) and/or TP53 mutation) 4, unmutated IGHV 2, beta-2 microglobulin >3.5 mg/L 2, advanced stage (Binet B/C or Rai I–IV) 1, age >65 1; max 10. Low 0–1, intermediate 2–3, high 4–6, very_high 7–10. Deterministic published score with citation; not a CLL diagnosis; not Shipp IPI; not MIPI. magent does not assay TP53, IGHV, or beta-2 microglobulin.

Zhou 2014 NCCN-IPI for DLBCL in the rituximab era: age (≤40 0, 41–60 1, 61–75 2, ≥76 3), LDH/ULN (≤1 0, >1–3 1, >3 2), Ann Arbor III or IV 1, major-organ extranodal (bone marrow, CNS, liver/GI tract, or lung) 1, ECOG ≥2 1; max 8. Low 0–1, low_intermediate 2–3, high_intermediate 4–5, high 6–8. Deterministic published score; not a DLBCL diagnosis or treatment choice; not Shipp IPI, not R-IPI, not CNS-IPI. magent does not assay LDH or stage lymphoma.

Condoluci 2020 IPS-E for asymptomatic early-stage chronic lymphocytic leukemia: unmutated IGHV 1, ALC >15 ×10^9/L 1, palpable lymph nodes 1; max 3. Low 0, intermediate 1, high 2–3. Time-to-first-treatment score, not a treatment start order; not CLL-IPI, Rai, or Binet. magent does not assay IGHV, count lymphocytes, or palpate nodes.

Thieblemont 2017 MALT-IPI (IELSG-19): age ≥70, Ann Arbor III or IV, LDH > ULN; 1 point each, max 3. Low 0, intermediate 1, high ≥2. Deterministic published score with citation; not a lymphoma diagnosis or treatment choice; original MALT-IPI, not Revised MALT-IPI (no MMS; age is ≥70 not >60), not Shipp IPI. magent does not stage lymphoma or assay LDH.

Maurer 2025 FLIPI24: 24-month event probability in newly diagnosed follicular lymphoma from age (nonlinear, inflection at 75), hemoglobin, WBC, LDH/ULN, and beta-2 microglobulin. Table S5 Cox algorithm assuming R-CHOP or B-R-like immunochemotherapy and 50% anti-CD20 maintenance. Low/intermediate/high at 0.10 and 0.15. Not Solal-Céligny FLIPI 2004. Not a diagnosis or treatment order. magent does not assay labs.

Absolute neutrophil count from WBC and neutrophil plus band percents. Bodey 1966 granulocyte bands. Deterministic published arithmetic with citation; not a diagnosis.

Binet 1981 CLL staging. Stage C if anemia (Hb <10 g/dL) or thrombocytopenia (platelets <100×10^9/L), regardless of lymphoid areas. Else stage B when involved_areas is 3-5, else stage A when 0-2. The five areas are cervical, axillary, and inguinal (unilateral or bilateral counts as one area each), plus spleen, plus liver; the caller assigns the count. Not a medical device, not a CLL diagnosis, and not Rai staging (Rai anemia is Hb <11).

Hasford 2011 EUTOS score for baseline untreated chronic myeloid leukemia (CML). eutos_score = 4 * spleen_cm + 7 * basophils_percent, rounded to 1 decimal. Low if score ≤ 87; high if score > 87. spleen_cm is centimetres below the costal margin (0-40); basophils_percent is peripheral-blood basophils (0-100). Not a CML diagnosis and not a TKI choice.

Shipp 1993 IPI for aggressive non-Hodgkin lymphoma: age >60, Ann Arbor III or IV, extranodal sites >1, ECOG ≥2, LDH > ULN; 1 point each, max 5. Low 0–1, low_intermediate 2, high_intermediate 3, high 4–5. Deterministic published score with citation; not a lymphoma diagnosis or treatment choice; not age-adjusted IPI, not R-IPI, not NCCN-IPI. magent does not assay LDH.

Rai 1975 original CLL staging (stages 0-IV). Returns rai_stage 0-4 from caller-assigned lymphadenopathy, hepatosplenomegaly (spleen or liver or both), anemia (Hb <11 g/dL), and thrombocytopenia (platelets <100,000/mm3). Highest applicable: thrombocytopenia 4, else anemia 3, else organomegaly 2, else nodes 1, else 0 (lymphocytosis only). Not a CLL diagnosis; magent does not examine the patient or read a CBC. Not modified Rai. Not Binet (Binet C is Hb <10).

Schmitz 2016 CNS-IPI: Shipp IPI factors (age >60, ECOG ≥2, LDH > ULN, Ann Arbor III or IV, extranodal sites >1) plus kidney and/or adrenal involvement; 1 point each, max 6. Low 0–1, intermediate 2–3, high 4–6. CNS relapse risk after R-CHOP in DLBCL. Deterministic published score; not a CNS prophylaxis or LP order; not NCCN-IPI; not R-IPI; not a DLBCL diagnosis. magent does not stage lymphoma or image kidneys.

NCI CTC v2.0 Mucositis due to radiation (Trotti 2000). none → 0; erythema → 1; patchy_pseudomembrane (≤1.5 cm, noncontiguous) → 2; confluent_pseudomembrane (contiguous >1.5 cm) → 3; necrosis_or_deep_ulcer (may include bleeding not induced by minor trauma) → 4. magent does not examine the mucosa. Not CTC stomatitis/pharyngitis, CTCAE v3/v4/v5, or WHO mucositis. Not a diagnosis or medical device.

Adult ASTCT ICANS consensus grade (Lee 2019 Table 6). Grade is the most severe of ICE, depressed LOC, seizure, deep focal motor weakness, and ICP/edema. ICE 10 is 0; 7-9 is 1; 3-6 is 2; 0-2 is 3; ICE 0 is 4 if unarousable. Not CRS, not pediatric CAPD, and not the 10-item ICE test. magent does not perform ICE testing or examine the patient. Not a medical device.